RXi Pharmaceuticals Corp (NASDAQ: RXII) is climbing in the pre-market hours this morning, and for good reason. The company announced yesterday that it would be attending the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer. Perhaps more importantly, the company will be presenting. Today, we’ll talk about:
- The news;
- what we’re seeing from RXII stock as a result; and
- what we’ll be watching for ahead.
RXII Attends The Conference Today
While the news was released yesterday, RXi Pharmaceuticals is seeing stronger movement in the market today. That’s because today starts the conference. The 33rd Annual Meeting & Pre Conference begins today and ends on the 11th of November. So, what’s the big deal?
Not only will RXII be presenting at the conference, these events bring key figures together. While attending the conference, the company will have the ability to mingle with big time investors, potential partners, and other key players that can help to bring the company to success.
Morever, RXII will be presenting data that demonstrates the potential of sd-rxRNA to improve NK cell potency in adoptive cell transfer. The presentation will take place on Saturday between 12:20 and 1:50 pm ET and again between 7:00 and 8:30 pm. The poster will also be available on the company’s investor relations website.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of RXi Pharmaceuticals, the news proved to be positive. During this conference, the company has the potential to make key relationships and attract the attention of deep-pocketed investors. So, it comes as no surprise that excited investors are sending the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (7:42), RXII is trading at $0.48 per share after a gain of $0.035 per share or 7.81% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on RXII. In particular, we’re interested in following the continued development of sd-rxRNA as well as the rest of the company’s relatively robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!